stoxline Quote Chart Rank Option Currency Glossary
Anixa Biosciences, Inc. (ANIX)
3.12  0.02 (0.65%)    04-19 16:00
Open: 3.1
High: 3.2
Volume: 32,691
Pre. Close: 3.1
Low: 3.05
Market Cap: 100(M)
Technical analysis
2024-04-19 5:07:44 PM
Short term     
Mid term     
Targets 6-month :  4.31 1-year :  4.78
Resists First :  3.69 Second :  4.09
Pivot price 3.18
Supports First :  3.02 Second :  2.52
MAs MA(5) :  3.11 MA(20) :  3.19
MA(100) :  3.8 MA(250) :  3.57
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  11.8 D(3) :  14.1
RSI RSI(14): 42.7
52-week High :  5.13 Low :  2.75
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ANIX ] has closed above bottom band by 27.0%. Bollinger Bands are 69.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.2 - 3.22 3.22 - 3.23
Low: 3.02 - 3.03 3.03 - 3.05
Close: 3.1 - 3.12 3.12 - 3.14
Company Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Headline News

Thu, 18 Apr 2024
Anixa Biosciences adds Dr. Sanjay Juneja to advisory board - India

Thu, 18 Apr 2024
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board - BioSpace

Fri, 22 Mar 2024
Anixa Biosciences Stockholders Affirm Confidence and Oversight - - TipRanks

Wed, 20 Mar 2024
Should You Buy Anixa Biosciences Inc (ANIX) Stock on Wednesday? - InvestorsObserver

Thu, 14 Mar 2024
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties - BioSpace

Sat, 17 Feb 2024
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 32 (M)
Held by Insiders 3.038e+007 (%)
Held by Institutions 4.9 (%)
Shares Short 618 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 744.7 %
Return on Equity (ttm) -28.1 %
Qtrly Rev. Growth 210000 %
Gross Profit (p.s.) 0
Sales Per Share -49.45
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales -0.07
Price to Cash Flow 3.52
Stock Dividends
Dividend 0
Forward Dividend 575880
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android